Business Context and Reporting Period
This Form 8-K was filed by Aquestive Therapeutics, Inc. on August 6, 2019. The report serves to announce financial results for the three and six months ended June 30, 2019, and to disclose topline results from a clinical study for Libervant (Diazepam) Buccal Film.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K.
Material Changes
The filing references a comparison of financial results between the periods ended June 30, 2019, and June 30, 2018. However, the specific material changes or variances between these periods are not described in the text of this report.
Guidance, Outlook, and Other Events
- Clinical Study Results: The Company announced topline results from the Libervant (Diazepam) Buccal Film Single Dose Crossover Study. Specific data points from the study are not included in this filing text.
- Emerging Growth Company Status: The registrant is identified as an emerging growth company.
- Legal Disclaimer: Information furnished in Items 2.02 and 7.01 is not deemed "filed" under the Exchange Act and is not subject to the liabilities of Section 18.
Investor Verification Checklist
- Review Exhibit 99.1 for specific revenue, net loss, and cash position figures for the three and six months ended June 30, 2019.
- Examine Exhibit 99.2 for detailed topline data regarding the Libervant (Diazepam) Buccal Film Single Dose Crossover Study.
- Verify the impact of the clinical study results on the Company's future product pipeline and regulatory strategy.
- Confirm the Company's cash runway and liquidity status as detailed in the referenced press release.